CD20 Antibody (BC-1): sc-58983
- CD20 Antibody (BC-1) is a mouse monoclonal IgM, cited in 2 publications, provided at 100 µg/ml
- raised against chronic lymphocytic leukemia cells of human origin
- recommended for detection of CD20 of human origin by WB, IP, IF, IHC(P) and FCM
- See CD20 (D-10): sc-393894 for CD20 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for CD20 Antibody (BC-1). This work is in progress.
QUICK LINKS
SEE ALSO...
CD20 Antibody (BC-1) is a mouse monoclonal IgM antibody that detects CD20 in human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and flow cytometry (FCM). Anti-CD20 antibody (BC-1) targets CD20, a crucial leukocyte surface antigen characterized by four transmembrane regions and cytoplasmic N- and C-termini. The cytoplasmic domain of CD20 contains multiple phosphorylation sites, which can lead to the generation of different isoforms, thereby influencing functional diversity. CD20 is primarily expressed on B cells and has been identified on both normal and neoplastic T cells, highlighting relevance in various immune responses and potential roles in cancer biology. CD20 acts as a calcium-permeable cation channel, playing a significant role in cellular signaling by facilitating the transition from G0 to G1 phase of the cell cycle, particularly in response to insulin-like growth factor 1 (IGF-1). CD20 activation is mediated by the IGF-1 receptor through alpha subunits of heterotrimeric G proteins, leading to a marked increase in DNA synthesis, which involves basic helix-loop-helix leucine zipper transcription factors. This intricate regulation of CD20 underscores importance in both normal immune function and pathological conditions, making CD20 (BC-1) monoclonal antibody an essential tool for researchers studying B cell biology and related diseases.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
CD20 Antibody (BC-1) References:
- Anti-CD20 antibody therapy for B-cell lymphomas. | Maloney, DG. 2012. N Engl J Med. 366: 2008-16. PMID: 22621628
- CD20 role in pathophysiology of Hodgkin's disease. | Santos, MAO. and Lima, MM. 2017. Rev Assoc Med Bras (1992). 63: 810-813. PMID: 29239464
- The applications of anti-CD20 antibodies to treat various B cells disorders. | Payandeh, Z., et al. 2019. Biomed Pharmacother. 109: 2415-2426. PMID: 30551501
- CD3+CD20+ T cells and their roles in human diseases. | Chen, Q., et al. 2019. Hum Immunol. 80: 191-194. PMID: 30639700
- Binding mechanisms of therapeutic antibodies to human CD20. | Kumar, A., et al. 2020. Science. 369: 793-799. PMID: 32792392
- Distinct mechanisms underlying therapeutic potentials of CD20 in neurological and neuromuscular disease. | Chen, TX., et al. 2022. Pharmacol Ther. 238: 108180. PMID: 35367516
- Rational Protein Design Yields a CD20 CAR with Superior Antitumor Efficacy Compared with CD19 CAR. | Chen, X., et al. 2023. Cancer Immunol Res. 11: 150-163. PMID: 36409926
- Intrathecal CD8+CD20+ T Cells in Primary Progressive Multiple Sclerosis. | von Essen, MR., et al. 2023. Neurol Neuroimmunol Neuroinflamm. 10: PMID: 37369602
- Targeting malignant melanoma cells expressing the protein CD20 enhances BRAF-targeted treatment. | . 2024. Br J Dermatol. 190: e58. PMID: 38630926
- A personalized approach for anti-CD20 therapies in multiple sclerosis. | Hogenboom, L., et al. 2024. Mult Scler Relat Disord. 91: 105851. PMID: 39236647
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CD20 Antibody (BC-1) | sc-58983 | 100 µg/ml | $322.00 |